AdvanCell Enters Into Strategic Collaboration with Lilly to Advance Novel Targeted Alpha Therapies for the Treatment of Cancer
AdvanCell, a clinical-stage radiopharmaceutical company specializing in targeted alpha therapies, today announced an expansion to the scope and breadth of its strategic collaboration with Eli Lilly and Company to research and develop innovative treatments for various cancers.
Under this new agreement, the parties will leverage AdvanCell’s proprietary Pb-212 production technology and radionuclide development infrastructure and Lilly’s drug candidate programs and extensive expertise in drug development to facilitate the development and accelerate the clinical advancement of an expanded portfolio of targeted alpha therapies.
AdvanCell’s competitive advantage in technology development and the infrastructure it has built to accelerate early-stage clinical trials in Australia enables AdvanCell to rapidly develop and progress novel Pb-212-containing radiotherapeutics from discovery into clinical trials.
“This collaboration with Lilly represents a significant milestone for AdvanCell, recognizing our company as one of the leaders in the Pb-212 targeted alpha therapy space,” said Andrew Adamovich, CEO of AdvanCell. “By combining our groundbreaking isotope production capabilities, our team’s expertise and infrastructure with Lilly’s pharmaceutical and oncology expertise and global scale, we aim to bring transformative treatments to patients with hard-to-treat cancers. It is especially pleasing to continue and expand our existing relationship.”
Jacob Van Naarden, President of Lilly Oncology, added, “Partnering with AdvanCell aligns with our commitment to advancing innovative radiopharmaceuticals. We are excited to explore the potential of Pb-212-based alpha therapies as we work to bring meaningful new treatments for patients.”
Financial terms of the agreement were not disclosed.
About AdvanCell
AdvanCell is dedicated to developing innovative cancer therapies that harness the power of targeted alpha-emitting radionuclides. By combining advanced manufacturing capabilities with cutting-edge science and clinical development capabilities, AdvanCell aims to deliver novel treatments that improve outcomes for cancer patients globally. For more information, visit www.advancell.com.au.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250210990350/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte to Showcase New Data from its Oncology Portfolio at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting23.4.2025 17:03:00 CEST | Press release
Incyte (Nasdaq: INCY) today announced that multiple abstracts featuring new data from its oncology portfolio will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 30 – June 3, 2025, in Chicago. “The data featured at the 2025 ASCO Annual Meeting, from both our approved medicines and early-stage pipeline, reflect our ongoing efforts to transform cancer care,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “We are advancing potential therapies across some of the most difficult-to-treat cancers and hematological diseases, including squamous cell anal cancer, ovarian cancer and myelofibrosis, with the hope of making a meaningful difference for these patients.” Key abstracts accepted for presentation: Oral Presentations INCB123667 Safety and Preliminary Efficacy from a Phase 1 Study of INCB123667, a Selective CDK2 Inhibitor, in Patients with Advanced Platinum-Resistant and Refractory Ovarian Cancer (OC) (Abst
LTIMindtree’s FY25 Revenue up 7% in INR23.4.2025 16:42:00 CEST | Press release
Order Inflow at USD 6 Billion, up 6% on full-year basis LTIMindtree [NSE: LTIM, BSE: 540005], a global technology consulting and digital solutions company, announced its consolidated results today for the fourth quarter and full year ended Mar 31, 2025, as approved by its Board of Directors. “We concluded FY25 with a revenue growth of 5% in constant currency terms and an EBIT margin of 14.5%. Our key verticals and a major geography drove our yearly growth despite an ongoing challenging macro environment. The robust order inflow, driven by a significant array of AI-led deal wins, illustrates the pervasive integration of AI across our service offerings. Venu Lambu’s transition to LTIMindtree has been seamless and supports our strategic goals. His growing understanding of the organisation, combined with our ability to secure large deals, strong presence in tech-intensive sectors, and robust balance sheet, positions us well to leverage the opportunities ahead of us.” - Debashis Chatterjee,
Next-Gen Cyber Guardians: Yubico Empowers Youth-Led Hackathons to Secure the Future23.4.2025 15:00:00 CEST | Press release
Yubico sponsored youth-led hackathons around the world foster collaboration, innovation, and hands-on cybersecurity experience for the next generation of cyber leaders In an era marked by escalating cyber threats, Yubico (NASDAQ STOCKHOLM: YUBICO), the leading provider of hardware authentication security keys, is proud to empower the future of cybersecurity leaders by recently providing YubiKeys to over 20 youth-led hackathon and tech events through its Secure It Forward program. Investing in youth-led organizations that run hackathons is a vital step for cybersecurity companies committed to fostering the next generation of security experts. Especially critical today in the ever-evolving security threat landscape, these events not only provide young innovators with hands-on experience in tackling real-world cyber threats but also help drive innovation, promote ethical hacking, and strengthen global efforts to secure the internet for businesses, individuals, and communities alike. “As w
Diligent Unveils AI Risk Essentials to Accelerate Risk Management and Elevate Governance23.4.2025 15:00:00 CEST | Press release
New AI-powered solution empowers organizations to identify, benchmark and mitigate risk efficiently Diligent, the leading governance, risk and compliance (GRC) SaaS company, today announced Diligent AI Risk Essentials (AI Risk Essentials), a new solution designed to initiate and strengthen an organization’s enterprise risk management (ERM) program. Supported by benchmarking risk data from SEC 10-K filings, AI Risk Essentials can be implemented in less than a week, enabling GRC professionals to immediately prepare for board-level discussions, swiftly identify risks, conduct risk assessments, implement mitigation strategies and monitor progress. AI Risk Essentials builds on Diligent’s track record of AI innovation, including the release of GovernAI, a suite of AI-powered features within the Diligent One Platform designed to streamline governance and risk workflows, saving valuable time for boards, executives and legal professionals while ensuring the highest levels of security and respon
Additional Keynote Speakers Announced: ISDA’s 39th Annual General Meeting in Amsterdam!23.4.2025 14:36:00 CEST | Press release
Join the International Swaps and Derivatives Association, Inc. (ISDA) at its 39th Annual General Meeting (AGM) in Amsterdam from Tuesday May 13 to Thursday May 15, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250423183579/en/ Keynote speakers include: Sarah Breeden, Deputy Governor for Financial Stability at the Bank of England José Manuel Campa, Chairperson, European Banking Authority Luis de Guindos, Vice-President, European Central Bank Jens Larsen, Head of Geoeconomics, Eurasia Group Steven Maijoor, Executive Board Member and Chair of Supervision, De Nederlandsche Bank Martin Moloney, Deputy Secretary General, Financial Stability Board Sid Nadella, Director, Global Head of Capital Markets Solutions, Google Cloud Other keynotes will be announced in the coming weeks. Accredited journalists are invited to attend the event and must register in advance. Please send your name, affiliation and contact details to Christo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom